A Study to Evaluate the Long-Term Safety and Effectiveness of Caplacizumab for Patients who Completed Study ALX0681-C301

Overview

About this study

The purpose of this study is to evaluate the long-term and repeated use safety and effectiveness of caplacizumab in patients who completed previous study ALX0681-C301.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria

  • Completed the Final (28 day) FU visit in Study ALX0681-C301
  • Is ≥18 years of age at the time of signing the informed consent form (ICF)
  • Provided informed consent prior to initiation of any study specific activity/procedure
  • Others as defined in the protocol

Exclusion Criteria

  • Not being able/willing to comply with the study protocol procedures
  • Currently enrolled in a clinical study with another investigational drug or device
  • Others as defined in the protocol

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Ronald Go, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20308687

Mayo Clinic Footer